Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05091775

The Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure

The Evaluation of the Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure in Post-Chemotherapy Cancer Patients - A Randomized Controlled Trial

Sponsor: Shiraz University of Medical Sciences

Conditions Diarrhea Fissure in Ano

Interventions Asacol is used to treat and prevent mild to moderate acute fissure disease

Updated 4 times since 2021 Last updated: Oct 20, 2021 Started: Jun 1, 2020 Primary completion: Aug 2, 2020 Completion: Jan 10, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Diarrhea and Fissure in Ano, this trial is completed. The trial is conducted by Shiraz University of Medical Sciences and has accumulated 4 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shiraz University of Medical Sciences

Data source: Shiraz University of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shiraz, Iran